• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.检测肺炎链球菌对氟喹诺酮类药物低水平耐药性的非分子检测方法。
Antimicrob Agents Chemother. 2006 Feb;50(2):572-9. doi: 10.1128/AAC.50.2.572-579.2006.
2
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.野生型、外排阳性或含有ParC或GyrA突变的肺炎链球菌分离株的单步氟喹诺酮耐药突变体的突变预防浓度。
Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004.
3
In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.新旧氟喹诺酮类药物对由外排介导的高水平环丙沙星耐药肺炎链球菌的体外活性。
Int J Antimicrob Agents. 2004 Aug;24(2):185-7. doi: 10.1016/j.ijantimicag.2004.01.012.
4
ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.在肺炎链球菌中,ParC和GyrA可能是某些氟喹诺酮类药物的可互换初始靶点。
Antimicrob Agents Chemother. 1999 Feb;43(2):302-6. doi: 10.1128/AAC.43.2.302.
5
In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.加替沙星在肺炎实验模型中对肺炎链球菌的体内药效学疗效:低水平氟喹诺酮耐药性对耐药突变体富集的影响
J Antimicrob Chemother. 2004 Sep;54(3):640-7. doi: 10.1093/jac/dkh393. Epub 2004 Aug 18.
6
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.化脓性链球菌emm6型中高水平氟喹诺酮耐药性的出现以及环丙沙星、左氧氟沙星和莫西沙星的体外耐药性选择。
J Antimicrob Chemother. 2009 May;63(5):886-94. doi: 10.1093/jac/dkp057. Epub 2009 Mar 11.
7
Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.加雷沙星对耐环丙沙星肺炎链球菌的药效学活性
J Antimicrob Chemother. 2006 Jul;58(1):112-6. doi: 10.1093/jac/dkl159. Epub 2006 Apr 27.
8
Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.具有拓扑异构酶IV重组基因的肺炎链球菌氟喹诺酮耐药菌株的适应性
Antimicrob Agents Chemother. 2008 Mar;52(3):822-30. doi: 10.1128/AAC.00731-07. Epub 2007 Dec 26.
9
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.肺炎链球菌耐氟喹诺酮临床分离株中一种假定外排机制的流行情况。
Antimicrob Agents Chemother. 1998 Aug;42(8):2032-5. doi: 10.1128/AAC.42.8.2032.
10
Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.呼吁国际上采用针对氟喹诺酮类药物和肺炎链球菌的微生物学断点。
Int J Antimicrob Agents. 2006 Sep;28(3):266-9. doi: 10.1016/j.ijantimicag.2006.04.007. Epub 2006 Aug 9.

引用本文的文献

1
Comparison of prognostic factors between bacteraemic and non-bacteraemic critically ill immunocompetent patients in community-acquired severe pneumococcal pneumonia: a STREPTOGENE sub-study.社区获得性重症肺炎链球菌肺炎中菌血症与非菌血症免疫功能正常的重症患者预后因素的比较:一项STREPTOGENE子研究
Ann Intensive Care. 2021 Oct 24;11(1):148. doi: 10.1186/s13613-021-00936-z.
2
Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study.宿主-病原体相互作用和免疫功能健全的危重症肺炎链球菌肺炎患者的预后:全国性前瞻性观察性 STREPTOGENE 研究。
Intensive Care Med. 2018 Dec;44(12):2162-2173. doi: 10.1007/s00134-018-5444-x. Epub 2018 Nov 19.
3
Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.耐药监测研究:一个多方面的问题——氟喹诺酮类药物的例子。
Infection. 2012 Jun;40(3):239-62. doi: 10.1007/s15010-012-0257-2. Epub 2012 Mar 30.
4
First molecular characterization of fluoroquinolone resistance in Aerococcus spp.气球菌属中氟喹诺酮耐药性的首次分子特征分析
Antimicrob Agents Chemother. 2011 Jan;55(1):451-2. doi: 10.1128/AAC.01065-10. Epub 2010 Nov 15.
5
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.肺炎链球菌中gyrA和parC突变的实时PCR检测
Antimicrob Agents Chemother. 2008 Nov;52(11):4155-8. doi: 10.1128/AAC.00082-08. Epub 2008 Aug 25.
6
Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.一名患有先前存在parC突变的肺炎链球菌感染的菌血症患者,使用左氧氟沙星治疗失败并导致死亡。
J Clin Microbiol. 2008 Apr;46(4):1558-60. doi: 10.1128/JCM.02066-07. Epub 2008 Feb 20.

本文引用的文献

1
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.美国耐左氧氟沙星的侵袭性肺炎链球菌:克隆传播的证据及肺炎球菌结合疫苗的影响
Antimicrob Agents Chemother. 2004 Sep;48(9):3491-7. doi: 10.1128/AAC.48.9.3491-3497.2004.
2
In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.加雷沙星(BMS-284756)与其他六种喹诺酮类药物相比,对肺炎链球菌、草绿色链球菌和粪肠球菌的体外活性。
Antimicrob Agents Chemother. 2003 Nov;47(11):3542-7. doi: 10.1128/AAC.47.11.3542-3547.2003.
3
Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.肺炎球菌肺炎中氟喹诺酮类和大环内酯类治疗失败及多重耐药菌株的选择
Emerg Infect Dis. 2003 Sep;9(9):1159-62. doi: 10.3201/eid0909.020810.
4
Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.肺炎链球菌的抗菌药物敏感性断点及parC基因第一步突变:重新定义氟喹诺酮类耐药性
Emerg Infect Dis. 2003 Jul;9(7):833-7. doi: 10.3201/eid0907.020589.
5
Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada.加拿大耐青霉素和耐环丙沙星肺炎链球菌的分子流行病学
Antimicrob Agents Chemother. 2003 Feb;47(2):804-8. doi: 10.1128/AAC.47.2.804-808.2003.
6
Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan.耐氟喹诺酮类肺炎链球菌菌株在日本老年患者中频繁出现。
Antimicrob Agents Chemother. 2002 Oct;46(10):3311-5. doi: 10.1128/AAC.46.10.3311-3315.2002.
7
Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.与肺炎链球菌体外筛选对莫西沙星耐药性相关的拓扑异构酶突变
Antimicrob Agents Chemother. 2002 Aug;46(8):2712-5. doi: 10.1128/AAC.46.8.2712-2715.2002.
8
Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.西班牙六种不同喹诺酮类药物对环丙沙星敏感性降低的肺炎链球菌临床呼吸道分离株的活性
Antimicrob Agents Chemother. 2002 Aug;46(8):2665-7. doi: 10.1128/AAC.46.8.2665-2667.2002.
9
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.对左氧氟沙星的耐药性与肺炎球菌肺炎治疗失败
N Engl J Med. 2002 Jul 4;347(1):65-7; author reply 65-7. doi: 10.1056/NEJM200207043470115.
10
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.对左氧氟沙星的耐药性与肺炎球菌肺炎治疗失败
N Engl J Med. 2002 Mar 7;346(10):747-50. doi: 10.1056/NEJMoa012122.

检测肺炎链球菌对氟喹诺酮类药物低水平耐药性的非分子检测方法。

Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.

作者信息

Varon Emmanuelle, Houssaye Serge, Grondin Sophie, Gutmann Laurent

机构信息

L.R.M.A., INSERM, U655, Université Paris 6, and Université Paris 5, 75270 Paris cedex 06, France.

出版信息

Antimicrob Agents Chemother. 2006 Feb;50(2):572-9. doi: 10.1128/AAC.50.2.572-579.2006.

DOI:10.1128/AAC.50.2.572-579.2006
PMID:16436712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1366886/
Abstract

With respect to pneumococci, there is a need to detect first-step mutants with reduced fluoroquinolone (FQ) susceptibility from which second-step, resistant mutants are likely to be selected in the presence of antipneumococcal FQs. Here, we describe an interpretative disk diffusion test, of which three options are presented, that allows the distinction between first- and second-step mutants. Using five FQ disks (pefloxacin, norfloxacin, levofloxacin, ciprofloxacin, and sparfloxacin, option 1), all known mechanisms of altered FQ susceptibility found in first-step mutants (ParC, ParE, GyrA, or efflux) and in second-step mutants (ParC and GyrA or ParE and GyrA) can be accurately detected, making this option a useful epidemiological tool. Using three FQ disks (pefloxacin, norfloxacin, and levofloxacin, option 2), the most prevalent FQ-resistant mutants, but not the first-step GyrA mutants, can be detected. With only two FQ disks (norfloxacin and levofloxacin) in the third and simplest option, first-step mutants can be distinguished from second-step mutants, however, without differentiation of ParC, ParE, or efflux alterations.

摘要

关于肺炎球菌,有必要检测氟喹诺酮(FQ)敏感性降低的第一步突变体,在使用抗肺炎球菌FQ的情况下,可能会从中选择第二步耐药突变体。在此,我们描述了一种解释性纸片扩散试验,该试验提供了三种选择,可区分第一步和第二步突变体。使用五个FQ纸片(培氟沙星、诺氟沙星、左氧氟沙星、环丙沙星和司帕沙星,选项1),可以准确检测到在第一步突变体(ParC、ParE、GyrA或外排)和第二步突变体(ParC和GyrA或ParE和GyrA)中发现的所有已知FQ敏感性改变机制,使该选项成为一种有用的流行病学工具。使用三个FQ纸片(培氟沙星、诺氟沙星和左氧氟沙星,选项2),可以检测到最常见的FQ耐药突变体,但不能检测到第一步GyrA突变体。在第三个也是最简单的选项中,仅使用两个FQ纸片(诺氟沙星和左氧氟沙星),可以区分第一步突变体和第二步突变体,然而,无法区分ParC、ParE或外排改变。